Lipocine Inc. Files 8-K: Other Events & Exhibits
Ticker: LPCN · Form: 8-K · Filed: 2024-11-18T00:00:00.000Z
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
TL;DR
Lipocine filed an 8-K on Nov 18, 2024, for other events and exhibits. No specific details yet.
AI Summary
Lipocine Inc. filed an 8-K on November 18, 2024, reporting other events and financial statements. The company, previously known as Marathon Bar Corp until November 30, 2011, is incorporated in Delaware and headquartered in Salt Lake City, Utah. The filing does not detail specific transactions or financial figures but serves as a notification of events and exhibit filings.
Why It Matters
This filing indicates Lipocine Inc. is providing updates or submitting required documentation to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain specific negative or positive news that would immediately impact risk.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- Marathon Bar Corp (company) — Former company name
- November 18, 2024 (date) — Date of report
- November 30, 2011 (date) — Date of former company name change
- 675 Arapeen Drive, Suite 202 (address) — Principal executive offices
- Salt Lake City, Utah 84108 (address) — Principal executive offices
- 001-36357 (other) — Commission File Number
FAQ
What specific 'Other Events' are being reported by Lipocine Inc. in this 8-K filing?
The provided text does not specify the 'Other Events' being reported, only that this section is included in the filing.
What financial statements or exhibits are being filed by Lipocine Inc. on November 18, 2024?
The filing indicates that 'Financial Statements and Exhibits' are part of the report, but the specific contents are not detailed in the provided text.
When did Lipocine Inc. change its name from Marathon Bar Corp?
Lipocine Inc. changed its name from Marathon Bar Corp on November 30, 2011.
What is the principal executive office address for Lipocine Inc.?
The principal executive offices of Lipocine Inc. are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
What is the Commission File Number for Lipocine Inc.?
The Commission File Number for Lipocine Inc. is 001-36357.
From the Filing
0001493152-24-046444.txt : 20241118 0001493152-24-046444.hdr.sgml : 20241118 20241118094509 ACCESSION NUMBER: 0001493152-24-046444 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241118 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241118 DATE AS OF CHANGE: 20241118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 241469963 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm false 0001535955 0001535955 2024-11-18 2024-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): November 18, 2024     LIPOCINE INC.   (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events     The Company issued a press release announcing the publication and discussion of LPCN 1148 Manuscript at The Liver Meeting (AASLD) 2024 Editor’s Cut Session which was held on November 16, 2024. The press release is filed as Exhibits 99.1.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   The following exhibits are filed with this report:   Exhibit No.   Description 99.1   Press Release announcing Publication and Discussion of LPCN 1148 Manus